At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 89 enrolled
Drug / intervention
Brinzolamide 1%/Brimonidine 0.2% ophthalmic suspension +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Prospective, Randomized, Single-Center Study to Evaluate 24-hour Intraocular Pressure Control With Brinzolamide 1%/Brimonidine 0.2% Fixed Dose Combination Therapy
In Brief
A Phase 4 clinical trial evaluating Brinzolamide 1%/Brimonidine 0.2% ophthalmic suspension and Timolol Maleate 0.5% for Open-Angle Glaucoma and Ocular Hypertension. Completed, enrolled 89 participants.
Detailed Summary
The purpose of this study is to evaluate intraocular pressure (IOP) over a 24-hour period using Simbrinza™ topical ophthalmic suspension.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOpen-Angle Glaucoma, Ocular Hypertension
Countries--
Collaborators--
Timeline
Phase 4CompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartOct 2013
First PostedNov 2013
Primary CompletionMar 2014
TodayJul 2026
First PostedNov 7, 2013
Enrollment StartOct 1, 2013
Primary CompletionMar 1, 2014
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 12.7 years ago
Interventions
Brinzolamide 1%/Brimonidine 0.2% ophthalmic suspensiondrug
Commercially marketed and approved for lowering IOP in patients with open-angle glaucoma and ocular hypertension.
Timolol Maleate 0.5%drug
Commercially marketed and approved for lowering IOP in patients with open-angle glaucoma and ocular hypertension.